Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced or Metastatic Urothelial Cancer

What we are studying

The purpose of this study is to test the safety and tolerability of the research study drug, pembrolizumab (MK-3475) and test the effectiveness of the research study drug pembrolizumab to see if it has anti-tumor activity in advanced/unresectable or metastatic urothelial cancers. This is a research study to test an investigational drug, pembrolizumab, which has been approved for use in certain types of adult melanoma however it has not been approved in any other cancers (such as advanced/unresectable or metastatic urothelial cancers). Subjects in this study will be assigned to receive the investigational study drug, pembrolizumab.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Ability to consent
  • Diagnosed with urothelial cancer of the renal pelvis
  • Ureter
  • Bladder or urethra

What is involved

  • Archived Tumor Tissue sample
  • Routine blood test
  • Pembrolizumab


Parking Compensation

Contact Information

Study Coordinator
Patricia Smith,RN

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.